logo-loader
viewFaron Pharmaceuticals Ltd

Faron Pharmaceuticals - Proactive One2One Investor Forum May 2019

Faron Pharmaceuticals Ltd’s (LON:FARN) chief executive Markku Jalkanen presents at the Proactive Investors One2One Investor Forum  in London May 2019.

For more information visit www.faron.com

Quick facts: Faron Pharmaceuticals Ltd

Price: 147.5 GBX

AIM:FARN
Market: AIM
Market Cap: £63.85 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Faron Pharmaceuticals Ltd named herein, including the promotion by the Company of Faron Pharmaceuticals Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

A 'thrilling' year ahead for Faron Pharmaceuticals with Phase III Traumakine...

Markku Jalkanen, chief executive at Faron Pharmaceuticals Oy (LON:FARN), caught up with Proactive following their £15mln funding aimed at accelerating the development of its two lead products. Jalkanen says the funds will allow them to prepare the way to market for Traumakine, a treatment...

on 21/2/18

2 min read